URSODEOXYCHOLATE AND METHOTREXATE FOR BILIARY CIRRHOSIS

熊去氧胆酸盐和甲氨蝶呤治疗胆汁性肝硬化

• 批准号: 6246362
• 负责人: JOHN R. LAKE
• 金额: $ 4.89万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-04 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246362
• 关键词: biliary tract disorder chemotherapy; biopsy; clinical chemistry; clinical research; combination chemotherapy; drug screening /evaluation; endoscopy; human subject; human therapy evaluation; methotrexate; primary biliary cirrhosis; ursodeoxycholate

The major thrust of this treatment study is to compare the effects of UDCA plus methotrexate versus UDCA plus placebo on the course of patients with primary biliary cirrhosis. GCRC will be utilized in the collection of data via lab draws, monitoring of patients, post-liver biopsy, post endoscopy, and facilitating other required tests.

这项治疗研究的主要目的是比较 UDCA+甲氨蝶呤与UDCA+安慰剂对患者病程的影响 原发性胆汁性肝硬化 GCRC将用于收集 通过实验室抽取数据，监测患者，肝活检后， 内窥镜检查，并促进其他所需的测试。